Our research found that social stigma perceptions were more common in type 1 diabetes than type 2, possibly because type 2 is less visible.
Our survey of 190 U.S. endocrinologists finds GLP-1 and SGLT2 prescribing at 90%+ and rising, while many patients resist starting basal insulin.
Results from dQ&A Patient Voice Q1 2025 Update
